BioSpace News Archive

BridgeBio Pharma, Inc. presented promising positive data from six participants dosed in CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease.

Scientists long thought that siblings born with ASD share more of their mother’s genome than their father’s.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the PEERLESS II trial, Inari’s third randomized controlled trial (RCT) in venous thromboembolism (VTE).

Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced new preclinical data discussed in a poster presentation at the American Thoracic Society (ATS) 2023 International Conference.

Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, announced the expansion of its research facilities and new collaborations with leading scientists at Fred Hutchinson Cancer Center and the Institute for Protein Design at the University of Washington School of Medicine.

Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Gene Editing & Therapy Summit on Wednesday, May 24, 2023 at 11:30 AM ET.

TellBio, Inc. announces publication of data that show the utility of CTCs isolated with TellDx to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a cohort of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who progress on endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibition.

aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2023 International Conference.

Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in multiple presentations at the World Orphan Drug Congress, taking place May 23-25, 2023.

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo ® Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira® (adalimumab). Initially approved as a pre-filled syringe, Cyltezo is indicated to treat multiple chronic inflammatory diseases.